---
title: "Summit says FDA sets Nov. 14, 2026 action date for ivonescimab lung cancer filing"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296901535.md"
description: "Summit Therapeutics announced that the FDA has set a PDUFA goal action date of November 14, 2026, for its Biologics License Application (BLA) for ivonescimab combined with platinum-doublet chemotherapy. This filing targets EGFR-mutated advanced non-squamous non-small cell lung cancer (NSCLC). The drug is currently under FDA review."
datetime: "2026-08-25T11:00:52.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296901535.md)
  - [en](https://longbridge.com/en/news/296901535.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296901535.md)
generator: "portal-rs"
---

# Summit says FDA sets Nov. 14, 2026 action date for ivonescimab lung cancer filing

-   Summit Therapeutics’ BLA for ivonescimab with platinum-doublet chemotherapy entered FDA review for EGFR-mutated advanced non-squamous NSCLC. \* PDUFA goal action date set for Nov. 14, 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Summit Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202608250700BIZWIRE\_USPR\_\_\_\_\_20260825\_BW415559) on August 25, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [SMMT.US](https://longbridge.com/en/quote/SMMT.US.md)

## Related News & Research

- [Akeso, Summit cancer drug confirms lung cancer survival benefit](https://longbridge.com/en/news/298059867.md)
- [Summit Therapeutics strengthened by positive ivonescimab survival results](https://longbridge.com/en/news/297927190.md)
- [BlossomHill Therapeutics to present updated Phase 1/2 SOLARA trial data on BH-30643 in EGFR-mutant NSCLC at WCLC 2026](https://longbridge.com/en/news/297641175.md)
- [Alexandria Real Estate Equities declares Q3 2026 dividend of R$ 0.63 per unit](https://longbridge.com/en/news/297928934.md)
- [Quanta Services announces dividend of R$ 0.03 per unit for Q3 2026](https://longbridge.com/en/news/297931955.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**